Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:NXNN
CUSIPN/A
Phone844-919-9990
Debt
Debt-to-Equity Ratio0.25
Current Ratio0.87
Quick Ratio0.52
Price-To-Earnings
Trailing P/E Ratio-2.20
Forward P/E Ratio-3.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.30 million
Price / Sales4.78
Cash FlowN/A
Price / CashN/A
Book Value$6.10 per share
Price / Book1.31
Profitability
EPS (Most Recent Fiscal Year)($3.64)
Net Income$-2,170,000.00
Net Margins-7.70%
Return on Equity-40.39%
Return on Assets-22.91%
Miscellaneous
Employees62
Outstanding Shares1,970,000
Market Cap$15.73 million
Nexeon Medsystems (OTCMKTS:NXNN) Frequently Asked Questions
What is Nexeon Medsystems' stock symbol?
Nexeon Medsystems trades on the OTCMKTS under the ticker symbol "NXNN."
How were Nexeon Medsystems' earnings last quarter?
Nexeon Medsystems Inc (OTCMKTS:NXNN) posted its earnings results on Monday, May, 21st. The company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.03. The firm earned $2.87 million during the quarter, compared to analyst estimates of $1.70 million. Nexeon Medsystems had a negative return on equity of 40.39% and a negative net margin of 7.70%. View Nexeon Medsystems' Earnings History.
When is Nexeon Medsystems' next earnings date?
What is the consensus analysts' recommendation for Nexeon Medsystems?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nexeon Medsystems in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nexeon Medsystems.
Who are some of Nexeon Medsystems' key competitors?
Some companies that are related to Nexeon Medsystems include Soleno Therapeutics (SLNO), Stereotaxis (STXS), Digirad (DRAD), Dynatronics (DYNT), Aradigm (ARDM), Nexeon Medsystems (NXNND), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), Precision Optics (PEYE), Vaso (VASO), CHF Solutions (CHFS), Fc Global Realty (FCRE), Escalon Medical (ESMC), Trimedyne (TMED) and Guided Therapeutics (GTHP).
Who are Nexeon Medsystems' key executives?
Nexeon Medsystems' management team includes the folowing people:
- Mr. William Rosellini M.B.A., J.D., MBA, Chairman & CEO (Age 38)
- Mr. Brian Blischak M.B.A., M.S., Pres & Chief Commercial Officer (Age 53)
- Mr. Christopher R. Miller, Chief Financial Officer (Age 48)
- Mr. Daniel Powell, VP of Sales & Marketing (Age 43)
- Dr. Emily Hamilton Rosellini, Director of Emerging Therapy for NXPROC (Age 37)
Has Nexeon Medsystems been receiving favorable news coverage?
Headlines about NXNN stock have trended somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nexeon Medsystems earned a daily sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the company an impact score of 49.14 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Nexeon Medsystems.
How do I buy shares of Nexeon Medsystems?
Shares of NXNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nexeon Medsystems' stock price today?
One share of NXNN stock can currently be purchased for approximately $8.00.
How big of a company is Nexeon Medsystems?
Nexeon Medsystems has a market capitalization of $15.73 million and generates $3.30 million in revenue each year. The company earns $-2,170,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Nexeon Medsystems employs 62 workers across the globe.
How can I contact Nexeon Medsystems?
Nexeon Medsystems' mailing address is 1910 PACIFIC AVENUE SUITE 20000, DALLAS TX, 75201. The company can be reached via phone at 844-919-9990 or via email at [email protected]
MarketBeat Community Rating for Nexeon Medsystems (OTCMKTS NXNN)
MarketBeat's community ratings are surveys of what our community members think about Nexeon Medsystems and other stocks. Vote "Outperform" if you believe NXNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
